Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

In clinical trials, researchers have found that when T cells are incubated ex vivo in rapamycin (an inhibitor of mTOR), instead of dying, T cells can overcome the rapamycin effect and survive the culture system.

In this situation, the cells are being starved ex vivo, but signaling remains to keep them growing and have them emerge as healthy cells. Fowler notes that this process is somewhat paradoxical. Fowler has studied T-rapa cells in a phase II clinical trial after low-intensity allogeneic hematopoietic cell transplantation.

Daniel H. Fowler, MD

Articles

Dr. Fowler on the Mechanism of Action of T-rapa Cells